B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples
Linus D. Kloker, Robert Rottscholl, Jonas S. Heitmann, Peter Bronsert, David Braig, Katrin Benzler, Lars Zender, Christoph K. W. Deinzer · 2026
Read B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples by Linus D. Kloker, Robert Rottscholl, Jonas S. Heitmann, Peter Bronsert, David Braig, Katrin Benzler, Lars Zender, Christoph K. W. Deinzer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13251000.txt.
Description
Kloker and colleagues measure a drug target called B7-H3 across many bone and soft tissue sarcomas. Their 2026 BMC Cancer study stains one hundred thirty-three pre-treatment samples from two German sarcoma centers. B7-H3 therapies are rising for solid tumors, but sarcoma data had covered only a few subtypes before this work.
Nearly every sample carried the target on its cell surfaces, and about one fifth scored high. Levels ran highest in pleomorphic liposarcoma, osteosarcoma, and angiosarcoma, and lowest in certain fatty and cartilage tumors. Higher scores tracked with higher tumor grade across all subtypes. Starting levels predicted freedom from events, though not overall survival, marking B7-H3 as a strong candidate target for high-grade sarcomas.
Catalog record
| CREATOR | Linus D. Kloker, Robert Rottscholl, Jonas S. Heitmann, Peter Bronsert, David Braig, Katrin Benzler, Lars Zender, Christoph K. W. Deinzer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |